Abstract | BACKGROUND: METHODS: RESULTS:
Glycated hemoglobin decreased significantly from 8.2 ± 1.5 to 6.7 ± 0.9% at the end of follow-up (mean 7.2 ± 2.5 years) in the SIK/IAK and remained constant in IIT (7.8 ± 1.0% and 7.6 ± 1.0) and WLI (7.8 ± 0.8 and 7.9 ± 1.0%). Daily insulin requirement decreased from 0.53 ± 0.15 to 0.29 ± 0.26 U/kg and remained constant in IIT (0.59 ± 0.19 and 0.58 ± 0.23 U/kg) and in WLI (0.76 ± 0.28 and 0.73 ± 0.11 U/kg). Severe hypoglycemia dropped in SIK/IAK from 4.5 ± 9.7 to 0.3 ± 0.7/patient-year and remained constant in IIT (0.1 ± 0.7 and 0.2 ± 0.8/patient-year). Detailed cost analysis revealed US $57,525 of additional cost for islet transplantation 5 years after transplantation. Based on a 5- and 10-year analysis, cost neutrality is assumed to be achieved 15 years after transplantation. CONCLUSIONS:
|
Authors | Philipp A Gerber, Rebecca Locher, Richard A Zuellig, Oliver Tschopp, Evelyne Ajdler-Schaeffler, Philipp Kron, Christian Oberkofler, Michael Brändle, Giatgen A Spinas, Roger Lehmann |
Journal | Transplantation
(Transplantation)
Vol. 99
Issue 10
Pg. 2174-80
(Oct 2015)
ISSN: 1534-6080 [Electronic] United States |
PMID | 25905979
(Publication Type: Journal Article)
|
Chemical References |
- Blood Glucose
- Hemoglobins
- Insulin
|
Topics |
- Adult
- Blood Glucose
(chemistry)
- Cardiovascular Diseases
(blood)
- Cohort Studies
- Diabetes Mellitus, Type 1
(blood)
- Female
- Follow-Up Studies
- Health Care Costs
- Hemoglobins
(chemistry)
- Humans
- Hypoglycemia
(blood, complications, therapy)
- Immunosuppression Therapy
- Insulin
(blood, therapeutic use)
- Islets of Langerhans Transplantation
(methods)
- Kidney Failure, Chronic
(blood)
- Kidney Transplantation
(methods)
- Male
- Middle Aged
- Pancreas Transplantation
- Risk Factors
- Time Factors
- Treatment Outcome
- Waiting Lists
|